Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q3 FY23
Investor Presentation
Q4 FY19
Bearish
4
Neutral
8
Bullish
2
Bearish
5
Neutral
8
Bullish
33
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
220.65 | 2,721 Cr | -80.49 | 2.27 | 0.27 | 3.03 | 3.56 | -1.43 | ||
1408.80 | 2,413 Cr | 55.06 | 7.04 | 0.02 | 11.73 | 17.24 | 6.82 | ||
151.30 | 2,372 Cr | 146.79 | 0.36 | 0.00 | 1.46 | 2.66 | 0.14 | ||
480.65 | 2,123 Cr | 85.18 | 10.32 | 0.00 | 2.91 | 2.79 | 1.46 | ||
934.45 | 2,079 Cr | 48.51 | 6.01 | 0.00 | 12.39 | 17.21 | 8.31 | ||
326.65 | 2,001 Cr | -224.30 | 2.46 | 0.00 | -2.93 | -2.42 | -0.71 | ||
215.85 | 1,993 Cr | 62.70 | 1.95 | 0.09 | -7.71 | 1.93 | 1.22 | ||
| Median: 7 Co. | — | 326.65 | 2,123 Cr | 55.06 | 2.46 | 0.00 | 2.91 | 2.79 | 1.22 |
Upcoming Result Date: Nov 04, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Fredun Pharmaceuticals Ltd (FREDUN) is currently trading at 1,448.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company focused on formulations, pet-care products and diagnostics, operating manufacturing at Palghar and exporting finished formulations to over 40 countries; it also runs the Fredun GX generics brand and a pet-commerce/service ecosystem under Wagr and subsidiary Fredun Retail Pvt Ltd. Q1 FY27 performance was a sharp inflection: consolidated standalone income reached INR228.25 crore, up 90.44% YoY, with EBITDA INR32.78 crore (+92.9%) and net profit INR13.17 crore (+94.6%), reflecting expanded operating margins and improved cash flow metrics that management attributes to stronger orders, inventory positioning and wider product penetration. Management projects sustained high growth with blended company growth guidance around 30%–35% for the next 3 years, driven by new-age brands growing 35%–45% and vintage business at 15%–20%; Fredun expects pet-care, functional foods and GX penetration to be major engines alongside planned manufacturing scale-up. Fredun is building a vertically integrated pet-care ecosystem: Wagr e-commerce platform, diagnostics centres, functional foods and cat food launches, plus OEM capacity and acquisitions. This multi-pronged approach could shift revenue mix materially toward higher-margin pet and nutraceutical segments over the medium term. Working capital and inventory management are front-of-mind; company reported a run-rate of ~INR850 crore and working capital around INR170–175 crore with a target to reduce inventory days toward 110–125 days while sustaining growth, implying ongoing cash conversion and interest-cost improvements.
Over the past 52 weeks, Fredun Pharmaceuticals Ltd has traded between a low of ₹454.05 and a high of ₹1,666.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fredun Pharmaceuticals Ltd has a market capitalization of approximately 2,412.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fredun Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.06 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,412.72 Cr, Fredun Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fredun Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fredun Pharmaceuticals Ltd is 55.06. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is pivoting from lower-margin OEM and contract manufacturing toward a 100% own-brand mix across branded generics and wellness, with a stated target timeline of 2029.
Net profit was ₹6.77 crore and total income was ₹119.86 crore for the quarter ended June 2025, as reported in the update.
Standalone net sales were Rs 159.93 crore for the quarter ended December 2025.
Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company focused on formulations, pet-care products and diagnostics, operating manufacturing at Palghar and exporting finished formulations to over 40 countries; it also runs the Fredun GX generics brand and a pet-commerce/service ecosystem under Wagr and subsidiary Fredun Retail Pvt Ltd.
Q1 FY27 performance was a sharp inflection: consolidated standalone income reached INR228.25 crore, up 90.44% YoY, with EBITDA INR32.78 crore (+92.9%) and net profit INR13.17 crore (+94.6%), reflecting expanded operating margins and improved cash flow metrics that management attributes to stronger orders, inventory positioning and wider product penetration.
Management projects sustained high growth with blended company growth guidance around 30%–35% for the next 3 years, driven by new-age brands growing 35%–45% and vintage business at 15%–20%; Fredun expects pet-care, functional foods and GX penetration to be major engines alongside planned manufacturing scale-up.
Fredun is building a vertically integrated pet-care ecosystem: Wagr e-commerce platform, diagnostics centres, functional foods and cat food launches, plus OEM capacity and acquisitions. This multi-pronged approach could shift revenue mix materially toward higher-margin pet and nutraceutical segments over the medium term.
Working capital and inventory management are front-of-mind; company reported a run-rate of ~INR850 crore and working capital around INR170–175 crore with a target to reduce inventory days toward 110–125 days while sustaining growth, implying ongoing cash conversion and interest-cost improvements.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,413 Cr
Low Risk
55.1
37.1
1.2
7.0
1,666.35
454.05
Sales CAGR
Profit CAGR
ROE
ROCE
